Search clinical trials for: Dapagliflozin Placebo

Total 54167 results

University of Guadalajara

Completed

Effect of Dapagliflozin Administration on Metabolic Syndrome, Insulin Sensitivity, and Insulin Secretion

Metabolic Syndrome X

Mexico
Wake Forest University Health Sciences

Recruiting

SNIFF - Combo INI+EMPA Trial

Cognitive Impairment | Alzheimer Disease | Mild Cognitive Impairment

United States
AstraZeneca
Bristol-Myers Squibb

Completed

A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise

Type 2 Diabetes

United States, Canada, Mexico, Russian Federation
Janssen-Cilag International NV

Completed

Effects of Canagliflozin on C-peptide Clearance in Healthy Volunteers

Healthy

Germany
Washington University School of Medicine
Juvenile Diabetes Research Foundation

Recruiting

Ketone Monitoring in T1D: Effect of SGLT2i During Usual Care and With Insulin Deficiency

Diabetes Mellitus, Type 1

United States
AstraZeneca
Biocard

Completed

An Open-label, Randomized, Crossover Study of Comparative Pharmacokinetics and Bioequivalence of Dapagliflozin + Metformin, 10 mg + 1000 mg Versus the Combined Use of Forxiga™, 10 mg and Two Glucophage® Long, ER Tablets, 500 mg Co-administered to Healthy Volunteers Under Standard Fed Conditions

Diabetes Mellitus, Type 2

Russian Federation
AstraZeneca

Completed

Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes

Type 2 Diabetes

Korea, Republic of, Mexico, South Africa, United States, Canada, Puerto Rico, Poland, Romania
University Health Network, Toronto

Recruiting

The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients (HALLMARK)

Kidney Transplant Recipients

Canada
AstraZeneca

Completed

A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease (Dapa-CKD)

Chronic Kidney Disease

United States, Canada, Spain, United Kingdom, Denmark, Germany, Korea, Republic of, Brazil, Hungary, Mexico, Peru, Philippines, Vietnam, China, Japan, Argentina, Ukraine, Poland, Russian Federation, India, Sweden
Kinderkrankenhaus auf der Bult
AstraZeneca; Alcedis GmbH

Completed

Pilot Study to Explore the Efficacy of DAPAglifozin as add-on to Closed-loop Control in Patients With Type 1 Diabetes (DapaDream)

Type1diabetes

Germany
AstraZeneca
Bristol-Myers Squibb

Completed

Safety and Efficacy of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes

Type 2 Diabetes Mellitus

United States, Canada, Mexico, India, Puerto Rico, Russian Federation, South Africa
University of Palermo
AstraZeneca; University of Catania

Unknown

Dapagliflozin, Cardio-Metabolic Risk Factors and Type-2 Diabetes

Type 2 Diabetes Mellitus

Italy
AstraZeneca
Bristol-Myers Squibb

Completed

Pharmacokinetic Drug Interaction Study With Dapagliflozin and Glimepiride in Healthy Subjects

Diabetes Mellitus, Type 2

Argentina
University Hospital, Basel, Switzerland

Completed

Effects of Empagliflozin an SGLT2-Inhibitor on Healthy Volunteers With Induced Hypotonic Hyponatremia - the DIVE Study (DIVE)

Inappropriate ADH Syndrome

Switzerland
University of Guadalajara

Unknown

Dapagliflozin on Blood Pressure Variability and Ambulatory Arterial Stiffness Index in Hypertension

Hypertension

Mexico
Boehringer Ingelheim
Eli Lilly and Company

Completed

Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Australia, Brazil, Canada, El Salvador, France, Korea, Republic of, New Zealand, Norway, Spain, Taiwan
University of Guadalajara

Completed

Effect of Dapagliflozin on Blood Pressure Variability in Prediabetes and Prehypertension

PreDiabetes | Prehypertension

Mexico
AstraZeneca

Completed

Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or Insulin

Type II Diabetes

United States
AstraZeneca
Bristol-Myers Squibb

Completed

A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone

Type 2 Diabetes

Mexico, United States, Argentina, Brazil, Canada
Genuine Research Center, Egypt
Hikma Pharma

Completed

Bioequivalence Study of Empagliflozin & Metformin HCL From Empagliform 12.5/1000 mg F.C.T (Hikma Pharma, Egypt) and Synjardy 12.5/1000 mg F.C.T (Boehringer Ingelheim International GmbH, Germany)

Healthy

Egypt
Chungbuk National University Hospital

Completed

Head-to-head Comparison of Empagliflozin and Dapagliflozin

Type2 Diabetes

Korea, Republic of
University of Campinas, Brazil
Fundação de Amparo à Pesquisa do Estado de São Paulo

Completed

Effects of SGLT2 Inhibitor on Hemodynamic Parameters in Resistant Hypertensive Subjects

Hypertension | Obesity | Diabetes Mellitus, Type 2 | Blood Pressure | Vascular Stiffness | Cardiac Hypertrophy | Microalbuminuria

Brazil
Sequana Medical N.V.

Recruiting

Management of Volume Overload HF Patients by Individual DSR Treatment adJustment-a clinicAl inVestigation of InfusatE2.0 (MOJAVE)

Heart Failure | Volume Overload

United States
Kinderkrankenhaus auf der Bult

Terminated

Study to Explore the Effect of Dapagliflozin and Stress in Adolescent and Adult Subjects With Type 1 Diabetes (T1D) (Dapa-Stress)

Type 1 Diabetes | Diabetic Ketoacidosis

Germany
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Assess the Pharmacokinetics and Pharmacodynamics of Canagliflozin (JNJ-28431754) in Healthy Indian Volunteers

Healthy

India
Janssen Research & Development, LLC

Completed

A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin XR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted Participants

Healthy

United States
Boehringer Ingelheim

Completed

4 Weeks Treatment With Empagliflozin (BI 10773) in Japanese Type 2 Diabetic Patients (T2DM)

Diabetes Mellitus, Type 2

Japan
Sequana Medical N.V.

Active, not recruiting

Safety & Feasibility of DSR TherApy in Heart FAiluRe pAtients With Persistent Congestion (SAHARA)

Heart Failure | Volume Overload

Georgia
Boehringer Ingelheim

Completed

Bioequivalence of Empagliflozin and Metformin Given as a Fixed Dose Combination Compared to Single Tablets

Healthy

Germany
Boehringer Ingelheim
Eli Lilly and Company

Completed

Empagliflozin and ACEi- Effects on Hyperfiltration: BETWEEN Study

Obesity | Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1

Canada
AstraZeneca
Uppsala Clinical Research, Uppsala, Sweden

Completed

A Study to Investigate Effects of Omega-3 Carboxylic Acids and Dapagliflozin on Liver Fat Content in Diabetic Patients (EFFECTII)

T2 Diabetes and Fatty Liver Disease (Non-alcoholic Origin)

Sweden
The University of Texas Health Science Center at...
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Recruiting

Ketones, SGLT2, HFrEF

Heart Failure With Reduced Ejection Fraction | Type2diabetes

United States
AstraZeneca

Completed

Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes

Type 2 Diabetes

United States, Puerto Rico, Mexico, Russian Federation, Romania, Poland, Czech Republic, United Kingdom
University of Pisa

Completed

Effects of Dapagliflozin+Saxagliptin in Addition to Metformin v/s Saxagliptin or Dapagliflozin in Patients With DM2.

Type2 Diabetes Mellitus

Italy
LG Chem

Completed

Trial to Evaluate the Efficacy on Glycemic Variability and Safety of Gemigliptin Compared With Dapagliflozin Added on Metformin Alone or Diabetes Medication Naïve Patient in Type 2 Diabetes Mellitus (Stable II Study)

Type 2 Diabetes Mellitus

Korea, Republic of
Vanderbilt University Medical Center
AstraZeneca

Completed

Efficacy and Safety of Dapagliflozin in Acute Heart Failure (DICTATE-AHF)

Heart Failure | Diabetes Mellitus, Type 2

United States
McGill University Health Centre/Research Institute...
Diabetes Canada

Recruiting

Effectiveness of Empagliflozin Added to Automated Insulin Delivery (AID) Systems in Adults With Type 1 Diabetes With Sub-optimal Glycemic Outcomes

Type 1 Diabetes

Canada
Boehringer Ingelheim

Completed

A Study to Test How Well Empagliflozin Works in Japanese People With Type 2 Diabetes Who Are Older Than 65 Years

Diabetes Mellitus, Type 2

Japan
Boehringer Ingelheim

Completed

This Study Combines Data From 3 Other Studies Testing Empagliflozin in Patients With Diabetes or With Chronic Heart Failure. The Study Looks at the Numbers of Patients Who Had Lower Limb Amputations

Diabetes Mellitus, Type 2

Germany
Boehringer Ingelheim

Completed

A Study to Test How Well Empagliflozin Works in Chinese Patients With Type 2 Diabetes Who Already Take Insulin

Diabetes Mellitus, Type 2

China
Boehringer Ingelheim
Eli Lilly and Company

Completed

EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)

Myocardial Infarction

United States, Spain, Australia, Denmark, Netherlands, Canada, China, Germany, Korea, Republic of, Israel, Hungary, Japan, Argentina, France, Romania, Russian Federation, Serbia, Ukraine, Poland, India, Brazil, Bulgaria
Janssen Research & Development, LLC
The George Institute for Global Health, Australia

Completed

Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy (CREDENCE)

Diabetes Mellitus, Type 2 | Diabetic Nephropathy

United States, Canada, France, Germany, Poland, Ukraine, United Kingdom, China, Taiwan, Spain, Argentina, Colombia, Mexico, Bulgaria, India, Malaysia, Romania, Serbia, South Africa, Japan, Australia, Korea, Republic of, Chile, New Zealand and more
Boehringer Ingelheim
Eli Lilly and Company

Completed

Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3)

Diabetes Mellitus, Type 1

United States, United Kingdom, Canada, Italy, Hungary, Spain, Sweden, Australia, Netherlands, France, Czechia, Finland, Germany, Greece, Ireland, Latvia, Mexico, New Zealand, Norway, Poland, Portugal, Romania, Russian Federation, South...
Janssen Research & Development, LLC

Completed

A Study of Canagliflozin and Metformin Immediate Release (50 mg/500 mg) FDC Tablets in Healthy Volunteers

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study of Canagliflozin and Metformin Immediate Release (150 mg/500 mg) FDC Tablets in Healthy Volunteers

Healthy

United States
Boston University
American Heart Association

Recruiting

Assessment of Dapagliflozin on Vascular Health in Patients With Type 2 Diabetes (SFRNDM2)

Diabetes Mellitus, Type 2 | Endothelial Dysfunction

United States
Centre Hospitalier Universitaire Dijon

Completed

Evaluate the Effects of Dapagliflozin in Patients With Type 2 Diabetes (Cinétique DAPA)

Type-2 Diabetes | Oral Antidiabetics

France
AstraZeneca
Parexel

Completed

A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration.

Type 2 Diabetes Mellitus

United States
University of Virginia
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

Effects of Empagliflozin on Cardiac Microvasculature and Insulin Sensitivity in Subjects With Type 2 Diabetes (EJB051)

Type2 Diabetes | Insulin Sensitivity

United States
Kobe University
Boehringer Ingelheim

Active, not recruiting

A Extension Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance ( EMPIRE-02 ) (EMPIRE-02)

Insulin Resistance - Type A | Insulin Resistance - Type B | Lipoatrophic Diabetes Mellitus | Insulin Resistance Syndrome

Japan

Search clinical trials for: Dapagliflozin Placebo

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Senegal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations